US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Investing.com -- Shares of Kymera Therapeutics Inc (NASDAQ:KYMR) surged 37.3% premarket following the announcement of encouraging Phase 1 trial results for KT-621, a novel oral STAT6 degrader. The company reported that the treatment achieved over 90% mean STAT6 degradation in blood at doses above 1.5 mg, with complete degradation in both blood and skin at all multiple ascending dose (MAD) levels equal to or greater than 50 mg.
The positive data, which exceeded Kymera’s target product profile, significantly derisks the program and has bolstered investor confidence in the potential of KT-621 as a treatment for IL-4/IL-13-driven allergic diseases. The results were highlighted as surpassing expectations, with KT-621 demonstrating a safety profile undifferentiated from placebo, no serious adverse events, and no treatment-related adverse events in more than one subject.
Kymera’s President and CEO, Dr. Nello Mainolfi, emphasized the exceptional nature of the KT-621 Phase 1 results and the potential of the company’s strategy to develop oral small molecules with the efficacy and safety of injectable biologics. The treatment’s impact on Th2 biomarkers was also noted to be in line with or superior to dupilumab, a marketed treatment for similar conditions.
The Phase 1 trial was a double-blind, placebo-controlled study with a total of 118 subjects, evaluating the safety and tolerability of KT-621. The trial also assessed pharmacokinetics and pharmacodynamics, revealing rapid absorption and dose-proportional increase in exposure, with complete STAT6 degradation in blood and skin at certain doses.
Kymera Therapeutics is actively recruiting for its BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD), with results expected in the fourth quarter of 2025. Additionally, two parallel Phase 2b trials in AD and asthma are planned to commence in the fourth quarter of 2025 and the first quarter of 2026, respectively.
The company’s announcement has been met with investor optimism, as reflected in the significant rise in stock price during the trading session.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.